Gamida and Lonza established a commercial manufacturing deal for Gamida's late-stage omidubicel for bone marrow transplant. The agreement provides for future commercial production after potential FDA approval of the drug.
Lonza to construct manufacturing site for Gamida's omidubicel
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.